

# OSTEOPENIA / OSTEOPOROSIS TREATMENT

If bone density T score shows between -1 and -2.5 osteopenia or greater than 2.5 osteoporosis, and the patient has been on calcium and Vitamin D supplements, a trial of formulary drugs is required before consideration for approval of any non-formulary drugs.

Formulary drugs include:

- Risedronate (Actonel)
- Alendronate (Fosomax)
- Raloxifene (Evista)
- Calcitonin (Miacalcin)

**The PA Nurse may approve FORTEO if the following criteria are met:**

- Pharmacy profile shows monthly fills for calcium, vitamin D, and osteoporosis drug for 24 months
- Current bone scan has a T score of -2.5 or more negative
- Member is currently not smoking or is enrolled in a smoking cessation program
- Documentation shows previous osteoporotic fracture

**The PA Nurse may approve renewals of FORTEO if the following criteria is met:**

- Pharmacy profile shows compliance with calcium and vitamin D
- Patient is compliant with daily injections
- Patient continues to not smoke

Approve for an additional 3 months up to a total of 12 months.

**Limitation:**

After 12 months of FORTEO, a bone scan must be done. Continued approval must be based on the T score being -2.5 or greater.

**If the request does not meet criteria, the request must be reviewed by a Medical Director.**

---

**References:** See attached "Up To Date" for literature review.

**Approved by:**

Pharmacy and Therapeutics Committee

Date: 5/20/04

**Approved by:** \_\_\_\_\_

Date: \_\_\_\_\_